Skip to content
Search

Latest Stories

Follow Us:
Top Stories

How the government can solve America's obesity epidemic

News

How the government can solve America's obesity epidemic
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Dying younger. Living harder. Going broke. It is difficult to overstate the longitudinal effects of excess weight in America.


An estimated seven in ten Americans are overweight or obese. The combination, according to the National Institutes of Health, results in an estimated 300,000 preventable deaths per year with extreme obesity lowering life expectancy by 14 years on average.

Added weight not only makes everyday life more difficult, but it also produces serious health consequences that include cardiovascular disease, diabetes, musculoskeletal disorders and cancer. In total, obesity costs an estimated $260 billion annually in inpatient and outpatient care.

Whether weight gain is caused primarily by genetics, societal influences or individual will, scientists aren’t altogether sure. What’s clear, however, is that most efforts to lose weight ultimately fail.

New Hope In Diabetes Drugs

Ozempic, one of a new class of medications, has been shown in studies to spur significant weight loss. The others include Mounjaro, Rybelsus and Wegovy with several new (and convenient, pill-based) options in development.

A Heavy Price For Weight Loss

Last year, more than five million Americans were prescribed one of these drugs for weight reduction.

The annual price of treatment ranges from $12,000 (Mounjaro) to upwards of $16,000 per year (Wegovy). As a result, most users are either wealthy or have generous health-insurance coverage.

But as more Americans seek these medications for moderate weight loss, not diabetes, insurers have started clamping down. They’ve issued threatening letters to doctors, warning they’ll be referred to state regulatory boards for writing “off-label” prescriptions.

The Ozempic Paradox: Highly Effective But Unaffordable

Ozempic and other medications that help with weight loss are part of an ongoing national debate in which two competing truths collide.

The first truth is that these drugs work, leading to significant and sustained weight reduction: 14 to 25 pounds per individual on average during the medication course. And while they’re not a replacement for proper nutrition, exercise or healthier living, they do reduce the likelihood of heart attack, stroke and cancer.

Second, despite the medical opportunity at hand, making these drugs available to all 100 million obese American adults would prove cost prohibitive for businesses, private insurers and the government.

This means that the medications could drastically rollback the nation’s $260 billion in obesity-related medical expenses each year, but prescribing them at today’s prices would cost more than $1.5 trillion annually—increasing national healthcare expenditures by as much as 25 percent.

What’s more, these medications are considered “forever drugs,” requiring users to either maintain their dosage or regain most of the weight they lost.

Insurers are eager to draw a line between those seeking prescriptions for appearance’s sake and those at heightened risk of disease or death. They’re happy to cover the latter but, as with cosmetic surgery, insurers believe patients should foot the bill for the former.

Lost in this debate is an important question: Why not figure out how to make these lifesaving drugs broadly available and affordable?

The U.S. Government Can Lead The Way

With hundreds of thousands of obesity-related deaths each year, the magnitude of the problem qualifies as an “epidemic” and justifies forceful government intervention.

The current administration, with congressional approval, could initiate a nationwide campaign to fight obesity, similar to Operation Warp Speed. The program, with a $10 billion upfront investment, led to the speedy development of a safe and effective coronavirus vaccine. The government then was able to purchase more than one billion doses at one-third the cost of the vaccine’s current list price.

Here’s how the administration could replicate Operation Warp Speed to fight the obesity epidemic without breaking the bank.

Operation: Slim Provisions

The government would invest $4 billion up front— twice the average R&D cost to bring a new drug to market.

In return for funding and a ten year contract, the first drugmaker to develop a safe and effective weight-loss drug would be required to sell that medication back to the government at $40 per dose (or $2,000 per patient/year), significantly below the retail price of Ozempic and similar drugs. The winning pharma company would benefit financially, earning up to $1.2 trillion in sales over the contract’s lifetime without having to shoulder R&D costs.

With the new medication in hand, government-sponsored health programs, Medicaid and Medicare, would make it available to all obese enrollees (roughly 60 million people) for the next decade.

And by providing the drug to more than half of all obese adults, the government would reduce medical expenses by up to $130 billion annually or $1.3 trillion over 10 years, making the effort cost-neutral for American taxpayers.

Risks vs. Rewards

The only financial risk to the government (outside of defending likely lawsuits) would be failing in its search for a new drug, thus wasting the

$4 billion of taxpayer money. But that’s a relatively insignificant sum compared to the potential healthcare benefits.

The role of government is to protect the health and financial well-being of the nation. Fulfilling that function led to a lifesaving Covid-19 vaccine. Doing so again is the best option our nation has to address America’s growing obesity epidemic.


Read More

A Sudden Vacuum: Unpacking Lindsey Graham’s Legacy and Implications for the GOP’s Senate Agenda

U.S. Sen. Lindsey Graham (R-SC) speaks during a Senate Appropriations Committee hearing on the FY2027 budget request in the Dirksen Senate Office Building on Capitol Hill on May 12, 2026 in Washington, DC.

(Photo by Chip Somodevilla/Getty Images)

A Sudden Vacuum: Unpacking Lindsey Graham’s Legacy and Implications for the GOP’s Senate Agenda

On July 11, 2026, South Carolina Senator Lindsey Graham unexpectedly passed away at age 71. The likely cause of death was a tear in the main vessel that carries blood out of the heart, otherwise known as aortic dissection. According to a medical examiner’s preliminary report, the aortic dissection itself was due to a “brief and sudden illness” known as arteriosclerotic cardiovascular disease, which hardened Graham’s arteries.

Graham’s death prompted widespread, bipartisan tributes from across the political spectrum. President Trump ordered all flags to be flown at half-mast in the senator’s honor, later exclaiming that “Lindsey will be greatly missed!!!” on social media. On the global stage, key international allies mourned the loss of a fierce advocate for overseas alliances, with tributes coming from Ukrainian President Volodymyr Zelenskyy, Israeli Prime Minister Benjamin Netanyahu, and German Chancellor Friedrich Merz.

Keep ReadingShow less
Rebuilding America’s Federal Data System for Trust and Accuracy

How the U.S. can rebuild and improve its federal data system by combining Census, citizen, AI, and nontraditional data for stronger public policy.

sankai/Getty Images

Rebuilding America’s Federal Data System for Trust and Accuracy

The business aphorism, “You can’t manage what you don’t measure,” applies to countries as well as corporations. The U.S. has relied since its founding on accurate Census, economic, and health and scientific data to set national policy. As an earlier Fulcrum article described, the Trump administration has put many data sources at risk, and advocates are working to save them. But they’re also asking: As we protect and rebuild the national data ecosystem, how do we make it better than it has been in the past?

I recently moderated a webinar on Meeting the Challenge of Measurement, co-sponsored by NAPA, CODE, and the Bridge Alliance, with four leaders in the field: Chris Jackson of the research firm SSRS, Beth Jarosz of the Association of Public Data Users, Francesca Perucci of Open Data Watch, and Dr. Stefaan Verhulst of the GovLab. I also interviewed former U.S. Comptroller Gene Ludwig, author of The Mismeasurement of America. Their insights, plus my organization’s recent work with USAFacts, provide three principles for moving forward.

Keep ReadingShow less
Woman struggling to pull blue donkey with rope

How can the Democratic Party regain public trust? Ronald Hirsch argues for a renewed mission centered on equality, opportunity, fiscal responsibility, and American democracy.

Klaus Vedfelt / Getty Images

Can the Democratic Party Still Lead?

During the 20th century and for the first part of the 21st, the Democratic Party certainly led the nation in advancing the cause of equality and the ability of people to pursue their right to life, liberty, and happiness. At the same time, they led the nation by increasing its military might and advancing its power around the world to protect the human rights of others.

The American worker would likely still be toiling for low wages in industrial hell-holes were it not for the laws that Democratic-led Congresses passed to increase the rights of workers vis-a-vis employers and the rights of unions. Black individuals and other people of color would still be burdened by widespread discrimination—official and otherwise—were it not for the laws that Democratic-led Congresses passed to protect their rights as American citizens. This is not to say that we have achieved equality, but we have made much progress.

Keep ReadingShow less
Old engraved illustration of Ulysses defying the Cyclops.

Old engraved illustration of Ulysses defying the Cyclops.

mikroman6/Getty Images

Odysseus Reimagined: Nolan’s Epic Explores What Makes a True Hero

Who is a hero? More importantly: what is a hero? What attributes are universally admired, inspiring glorious stories, ballads and songs, memorials and movies, all chronicling the hero’s bold adventures?

The Odyssey, a new release written and directed by Christopher Nolan, attempts to answer that question. Based on the ancient tales The Iliad and The Odyssey, written by Homer around 800 BC, the film stars Matt Damon as Odysseus and Anne Hathaway as Penelope, his loyal wife.

Keep ReadingShow less